Last reviewed · How we verify
recombinant anti-EGFR monoclonal antibody
recombinant anti-EGFR monoclonal antibody is a Small molecule drug developed by Sinocelltech Ltd.. It is currently in Phase 1 development. Also known as: SCT200.
At a glance
| Generic name | recombinant anti-EGFR monoclonal antibody |
|---|---|
| Also known as | SCT200 |
| Sponsor | Sinocelltech Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery (PHASE1, PHASE2)
- Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer (PHASE3)
- Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System (PHASE2)
- Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers (PHASE2, PHASE3)
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial (PHASE3)
- A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation (PHASE1)
- Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases (PHASE2)
- A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- recombinant anti-EGFR monoclonal antibody CI brief — competitive landscape report
- recombinant anti-EGFR monoclonal antibody updates RSS · CI watch RSS
- Sinocelltech Ltd. portfolio CI
Frequently asked questions about recombinant anti-EGFR monoclonal antibody
What is recombinant anti-EGFR monoclonal antibody?
recombinant anti-EGFR monoclonal antibody is a Small molecule drug developed by Sinocelltech Ltd..
Who makes recombinant anti-EGFR monoclonal antibody?
recombinant anti-EGFR monoclonal antibody is developed by Sinocelltech Ltd. (see full Sinocelltech Ltd. pipeline at /company/sinocelltech-ltd).
Is recombinant anti-EGFR monoclonal antibody also known as anything else?
recombinant anti-EGFR monoclonal antibody is also known as SCT200.
What development phase is recombinant anti-EGFR monoclonal antibody in?
recombinant anti-EGFR monoclonal antibody is in Phase 1.
Related
- Manufacturer: Sinocelltech Ltd. — full pipeline
- Also known as: SCT200
- Compare: recombinant anti-EGFR monoclonal antibody vs similar drugs
- Pricing: recombinant anti-EGFR monoclonal antibody cost, discount & access